Biotech Currents
Subscribe
Sign in
Home
Notes
Perspectives
BioCurrents Updates
Catalyst Table
Schedule
Archive
About
Biotech Perspective
Latest
Top
Discussions
The Friday Biotech Perspective #42
uniQure’s speculative Huntington’s catalyst soars because it was speculative
Oct 10
•
Bill Langbein
The Friday Biotech Perspective #41
A personal vaccine journey and … the Makary-Prasad-RFK Jr. guidance
Jun 2
•
Bill Langbein
The Friday Biotech Perspective #40
After the Whiplash
Apr 27
•
Bill Langbein
The Friday Biotech Perspective #39
Washington uncertainty, Trump tariffs dismantle global drug development
Apr 7
•
Bill Langbein
The Friday Biotech Perspective #38
Strong clinical performances still rise in Trump II bear market
Mar 16
•
Bill Langbein
The Friday Biotech Perspective #37
The Cost of Washington Chaos
Feb 8
•
Bill Langbein
The Friday Biotech Perspective #36
Inari, Intra-Cellular lead M&A first strikes in 2025
Jan 17
•
Bill Langbein
The Friday Biotech Perspective #35
A Championship Season for catalysts in 2024
Dec 31, 2024
•
Bill Langbein
The Friday Biotech Perspective #34
Summit Thera turns to China to reach the Summit … again
Dec 6, 2024
•
Bill Langbein
The Friday Biotech Perspective #33
Kura (KURA) secures major partnership … and stock declines?
Nov 23, 2024
•
Bill Langbein
The Friday Biotech Perspective #32
Were Coya’s mixed Alzheimer’s trial results a speedbump or partly by design?
Nov 8, 2024
•
Bill Langbein
The Friday Biotech Perspective #31
About All that Jazz
Oct 19, 2024
•
Bill Langbein
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
